|
Researchers: Tiotropium inhaler may raise mortality risk People who used a Spiriva Respimat inhaler to ease breathing problems linked to lung diseases such as chronic bronchitis and emphysema were 52% more likely to die compared with a placebo group, a 6,500-participant study published in the British Medical Journal found. Researchers estimated that there would be one additional death per 124 patients who used the device, possibly because it is delivering a greater concentration of the drug, known generically as tiotropium, than intended. ShareThis news summary appeared in ANA SmartBrief on 06/15/2011
View the original article: |
|
you rock linkedin!
